Biologic response modifiers in pediatric cancer.
Hematol Oncol Clin North Am
; 15(4): 723-40, ix, 2001 Aug.
Article
em En
| MEDLINE
| ID: mdl-11676281
Biologic response modifiers are becoming an important addition to surgery, chemotherapy, and radiotherapy in the management of cancer. As this field of research grows and expands, more biologic response modifiers will be incorporated into therapeutic regimens. By stimulating the immune system to eradicate minimal residual disease, these agents may improve the disease-free and long-term survival rates of patients with a variety of malignancies. The challenge is to incorporate biologic response modifiers into the treatment armamentarium in ways that will maximize their tumorigenicity.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Acetilmuramil-Alanil-Isoglutamina
/
Fatores Imunológicos
/
Neoplasias
Tipo de estudo:
Prognostic_studies
Idioma:
En
Revista:
Hematol Oncol Clin North Am
Ano de publicação:
2001
Tipo de documento:
Article
País de afiliação:
Estados Unidos